| mavoglurant (STP7) / STALICLA |
Parkinson disease-1: AFQ056 in Phase III development for the treatment of Parkinson's disease levodopa-induced dyskinesia. |
|
|
| Ongoing | 3 | 0 | RestOfWorld | mavoglurant (AFQ056) | Novartis | Parkinson's Disease | | | | |
NCT06136195: Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers |
|
|
| Not yet recruiting | 2 | 63 | US | Mavoglurant, STP7 | Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Consumption, Heavy Drinker, Alcohol Use Disorder (AUD) | 05/26 | 05/26 | | |
2010-019353-18: Two-period, single-dose pharmacokinetic study in male adolescent patients with Fragile X Syndrome (FXS). |
|
|
| | 1 | | NA | AFQ056, AFQ056, | Novartis Pharma Services AG, Novartis Pharma Services AG | Fragile X Syndrome | | | | |
| Completed | 1 | 34 | US | Mavoglurant, Placebo | Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Drinking | 07/23 | 07/23 | | |
| Recruiting | 1 | 20 | US | STP7 (mavoglurant) or Placebo, Cocaine, Saline infusion | Stalicla SA, National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder | 09/24 | 09/24 | | |
NCT05203965: Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant |
|
|
| Recruiting | 1 | 80 | US | Mavoglurant (AFQ056), Placebo | Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Familial Alcoholism Vulnerability | 06/25 | 06/25 | | |
| dipraglurant (ADX-48621) / Addex |
NCT05116813: Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy |
|
|
| Recruiting | 2/3 | 140 | US | Dipraglurant, ADX48621 | Addex Pharma S.A. | Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias | 12/23 | 12/23 | | |
NCT04857359: Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy |
|
|
| Recruiting | 2b | 140 | US | Dipraglurant, ADX48621, Placebo | Addex Pharma S.A. | Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias | 08/23 | 08/23 | | |
|
|
|
NCT05027997: Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm |
|
|
| Recruiting | 2a | 15 | US | Dipraglurant, ADX48621, Placebo | Addex Pharma S.A. | Blepharospasm, Dystonia | 12/21 | 12/21 | | |
| basimglurant (NOE-101) / Noema Pharma |
2021-001866-39: An international randomized clinical study, measuring safety and effectiveness of basimglurant for the treatment of pain in patients with Trigeminal Neuralgia Estudio clínico aleatorizado internacional, que mide la seguridad y la eficacia del basimglurant para el tratamiento del dolor en pacientes con neuralgia del trigémino |
|
|
| Not yet recruiting | 2/3 | 200 | Europe | basimglurant, NOE-101, Capsule | Noema Pharma, Noema Pharma AG, Noema Pharma | Trigeminal neuralgia Neuralgia del trigémino, Trigeminal neuralgia is a chronic pain condition affecting the trigeminal nerve in the face causing sudden, severe facial pain. La Neuralgia del trigémino (NT) es un dolor crónico que afecta al nervio trigémino de la cara causando dolor facial repentino e intenso., Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT05217628: An Efficacy and Safety Study of Basimglurant in Patients With Trigeminal Neuralgia. |
|
|
| Recruiting | 2/3 | 200 | Europe, US, RoW | Basimglurant, Placebo | Noema Pharma AG | Trigeminal Neuralgia | 01/25 | 01/26 | | |
2021-000838-34: Basimglurant in children, adolescents, and young adults with Tuberous Sclerosis Complex Basimglurant in bambini, adolescenti e giovani adulti affetti da complesso della sclerosi tuberosa. |
|
|
| Not yet recruiting | 2 | 67 | Europe | Basimglurant, [NOE-101], Capsule, hard | Noema Pharma AG, Noema Pharma, Noema Pharma AG, Noema Pharma | Tuberous Sclerosis Complex complesso della sclerosi tuberosa, Tuberous Sclerosis Complex is a genetic disorder of uncontrolled growth of numerous benign tumors in many parts of the body including the brain, and one of the leading genetic causes of epilepsy. È una malattia genetica caratterizzata dalla crescita incontrollata di numerosi tumori benigni in molte parti del corpo, compreso il cervello, ed è una delle principali cause genetiche dell'epilessia., Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT05059327: Basimglurant in Children, Adolescents, and Young Adults With TSC |
|
|
| Recruiting | 2 | 54 | Europe, US, RoW | Basimglurant with crossover to Placebo, Placebo with crossover to Basimglurant | Noema Pharma AG | Tuberous Sclerosis Complex | 11/24 | 01/26 | | |
| TMP-301 / Tempero Bio |
NCT06025396: Multiple Ascending Dose Study of TMP-301 in Healthy Subjects |
|
|
| Completed | 1 | 30 | US | TMP-301, Placebo | Tempero Bio, Inc., National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder, Substance Use Disorders, Healthy Volunteers | 12/23 | 01/24 | | |
